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Vascular Biology, University of Queensland, Brisbane, Qld 4072, AustraliaThe durability of all forms of open or percutaneous
revascularisation is affected by the development of
localised stenoses within the bypass graft or at the site
of endarterectomy, stent or angioplasty. The reported
incidence of significant restenosis has varied depen-
dent on initial procedure, site, case mix and definition,
but is greatest during the first 12 months (Table 1).1
Over the last 40 years tens of thousands of studies
have been carried out in an effort to understand or
reduce the incidence of restenosis, with two major
mechanisms identified as being responsible for the
luminal narrowing, namely intimal hyperplasia and
constrictive remodelling. Intimal hyperplasia is pro-
voked by changes in the balance of local cytokines
controlling vascular smooth muscle cell (VSMC)
proliferation, apoptosis and migration, brought about
by endothelial or medial injury and alterations in
haemodynamic forces. The overall vessel diameter
reduction that occurs in constrictive remodelling is
less well defined, but likely involves matrix turn-
over under the control of proteinases, particularly
metalloproteinases.
Experimental studies have investigated the value of
systemic therapies, using a variety of different agents,
in reducing restenosis development without identify-
ing a clear benefit in clinical trials. More recently,
interest has grown in therapy applied local to the site
of the initial procedure to reduce the subsequent
development of significant stenosis. The use of bare
metal stents (BMS) following angioplasty was shown
to reduce the incidence of restenosis following
percutanous coronary intervention, likely by reducing
the effect of constrictive remodelling.2 However,
stenting continued to provoke intimal hyperplasiaing author. Associate Professor Jonathan Golledge,
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fore, a number of adjuvant local therapies have been
developed. These local adjuvant treatments include
coating of the stent with anti-proliferative agents or
local gene therapy, and physical techniques such as
brachy- and photodynamic therapy. The most recent
interest has been provoked by the favourable results of
drug-eluting stents (DES), such as paclitaxel and
sirolimus-eluting stents, used in the coronary circula-
tion. In a recent meta-analysis the incidence of
angiographic restenosis was reduced markedly by
employing sirolimus (OR 0.06, 95% CI 0–0.34, 6.2%
DES v 37% BMS, nZ1335) or paclitaxel-eluting stents
(OR 0.23, 95% CI 0.07–0.40, 7.1% DES v 23.5% BMS,
nZ1154) at 12 months.3 Further DES releasing other
agents, such as those interfering with proliferative
genes, are under development. The local delivery of
DNA designed to stimulate over-expression of favour-
able proteins or reduce expression of unfavourable
proteins is also under development (often referred to
as gene therapy).4 To date most studies have been
carried out in vitro or in animal models but recently
human studies of VEGF gene transfer following
peripheral angioplasty has reported promising
results.4
Adjuvant physical therapies to reduce the develop-
ment of restenosis include external beam and intra-
luminal radiation and photodynamic therapy.5–10
Trials examining the effect of intra-coronary radiation
have been generally disappointing with a reduced
incidence of restenosis but an increased rate of throm-
botic vessel occlusion.5 A number of studies have
shown more encouraging results of external beam
irradiation and intraluminal radiation in reducing the
development of restenosis following femoral angio-
plasty.6 The exact role of such brachytherapy requires
further clarification and is likely to depend on the
method of administration and dosing regimen.Eur J Vasc Endovasc Surg 30, 571–572 (2005)
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Table 1. Approximate rate of reported restenosis rates following
various interventions1
Procedure 12 months (%) O12 months/year
Coronary artery bypass 10 2%
Coronary stenting 20 2%
Carotid endarterectomy 10 2%
Carotid stenting 10 Unclear
Infra-inguinal bypass 30 5%
Iliac angioplasty 30 5%
Iliac stenting 20 5%
Femoral angioplasty 40 5%
J. Golledge and J. H. Campbell572In this edition of The European Journal of Vascular
and Endovascular Surgery, Pai and colleagues investi-
gate the use of photodynamic therapy (PDT) to prevent
restenosis following iliac artery stenting in a rabbit
model.7 PDT involves the local activation of pre-
administered photosensitive agents by low power red
laser light, delivered via a specially constructed balloon
catheter, to produce reactive oxygen radicals which are
locally cytotoxic. Pai et al. found that administration of
5-aminolaevulinic acid 3 h prior to endovascular
illumination of the iliac artery markedly reduced the
development of intimal hyperplasia, as long as this was
carried out prior to stent deployment.7 While the
authors did not elucidate the mechanisms for this
favourable response, other experimental studies have
suggested that PDT not only induces VSMC apoptosis
but also inhibits VSMC migration into the intima by
causing a change in the extra cellular matrix which acts
as a barrier to cell movement.8,9 No large clinical trials
assessing the use of PDT at the time of stenting or
angioplasty have been reported to date. The results from
a randomised trial assessing PDT use at the time of
femoral angioplasty are awaited.10 Whether PDT will
come into clinical use will likely depend on the success
of developments in drug-eluting stents.Acknowledgements
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